Search

Your search keyword '"Ferrando, Cecile A."' showing total 423 results
Start Over Author "Ferrando, Cecile A."
423 results on '"Ferrando, Cecile A."'

8. Defining mechanisms of recurrence following apical prolapse repair based on imaging criteria

Author

Bowen, Shaniel T, Moalli, Pamela A, Abramowitch, Steven D, Lockhart, Mark E, Weidner, Alison C, Ferrando, Cecile A, Nager, Charles W, Richter, Holly E, Rardin, Charles R, Komesu, Yuko M, Harvie, Heidi S, Mazloomdoost, Donna, Sridhar, Amaanti, Gantz, Marie G, Albo, Michael E, Alperin, Marianna, Columbo, Joann, Curry, Jodi, Ferrante, Kimberly, Herrala, Kyle, Johnson, Sherella, Kirby, Anna C, Lukacz, Emily S, Ruppert, Erika, Wasenda, Erika, Diwadkar, Gouri B, Dyer, Keisha Y, Mackinnon, Linda M, Menefee, Shawn A, Tan-Kim, Jasmine, Zazueta-Damian, Gisselle, Amundsen, Cindy, Bruton, Yasmeen, Coleman-Taylor, Notorious, Gilliam, Robin, Harris, Acacia, Hayes, Akira, Kawasaki, Amie, Longoria, Nicole, McLean, Shantae, Raynor, Mary, Siddiqui, Nazema, Visco, Anthony G, Ballard, Alicia, Carter, Kathy, Ellington, David, Patel, Sunita, Saxon, Nancy, Varner, R Edward, Willis, Velria, Carberry, Cassandra, Douglas, Samantha, Hampton, B Star, Korbly, Nicole, Meers, Ann S, Myers, Deborah L, Sung, Vivian W, Viscione, Elizabeth-Ann, Wohlrab, Kyle, Box, Karen, Dunivan, Gena, Jeppson, Peter, Middendorf, Julia, Rogers, Rebecca G, Arya, Lily, Andy, Uduak, Butler, Norman, Cain, Doris, Carney, Teresa, Flick, Lorraine, Khanijow, Kavita Desai, Kingslee, Michelle, Lee, Daniel, O’Donnell, Patricia, Smith, Ariana, Thompson, Donna, Bonidie, Michael, Gruss, Judy, Lowder, Jerry, Shepherd, Jonathan, Sutkin, Gary, Zyczynski, Halina M, Barber, Matthew, Dastoli, Kathleen, Edington, Maryori, Graham, Annette, Krishnan, Geetha, Jelovsek, Eric, Paraiso, Marie Fidela R, Pung, Ly, Ferrando, Cecile, Walters, Mark, Meikle, Susan, Burd, Andrew, Burdekin, Kate, Glass, Kendra, Grant, Tracey, and Grey, Scott

Subjects
Clinical Research, Clinical Trials and Supportive Activities, Aged, Female, Gynecologic Surgical Procedures, Humans, Hysterectomy, Vaginal, Imaging, Three-Dimensional, Magnetic Resonance Imaging, Middle Aged, Pelvis, Recurrence, Treatment Failure, Uterine Prolapse, hysteropexy, magnetic resonance imaging, pelvic organ prolapse, prolapse surgery, transvaginal mesh, vaginal hysterectomy, Eunice Kennedy Shriver National Institute of Child Health and Human Development Pelvic Floor Disorders Network, Paediatrics and Reproductive Medicine, Obstetrics & Reproductive Medicine
Abstract

BackgroundProlapse recurrence after transvaginal surgical repair is common; however, its mechanisms are ill-defined. A thorough understanding of how and why prolapse repairs fail is needed to address their high rate of anatomic recurrence and to develop novel therapies to overcome defined deficiencies.ObjectiveThis study aimed to identify mechanisms and contributors of anatomic recurrence after vaginal hysterectomy with uterosacral ligament suspension (native tissue repair) vs transvaginal mesh (VM) hysteropexy surgery for uterovaginal prolapse.Study designThis multicenter study was conducted in a subset of participants in a randomized clinical trial by the Eunice Kennedy Shriver National Institute of Child Health and Human Development Pelvic Floor Disorders Network. Overall, 94 women with uterovaginal prolapse treated via native tissue repair (n=48) or VM hysteropexy (n=46) underwent pelvic magnetic resonance imaging at rest, maximal strain, and poststrain rest (recovery) 30 to 42 months after surgery. Participants who desired reoperation before 30 to 42 months were imaged earlier to assess the impact of the index surgery. Using a novel 3-dimensional pelvic coordinate system, coregistered midsagittal images were obtained to assess study outcomes. Magnetic resonance imaging-based anatomic recurrence (failure) was defined as prolapse beyond the hymen. The primary outcome was the mechanism of failure (apical descent vs anterior vaginal wall elongation), including the frequency and site of failure. Secondary outcomes included displacement of the vaginal apex and perineal body and change in the length of the anterior wall, posterior wall, vaginal perimeter, and introitus of the vagina from rest to strain and rest to recovery. Group differences in the mechanism, frequency, and site of failure were assessed using the Fisher exact tests, and secondary outcomes were compared using Wilcoxon rank-sum tests.ResultsOf the 88 participants analyzed, 37 (42%) had recurrent prolapse (VM hysteropexy, 13 of 45 [29%]; native tissue repair, 24 of 43 [56%]). The most common site of failure was the anterior compartment (VM hysteropexy, 38%; native tissue repair, 92%). The primary mechanism of recurrence was apical descent (VM hysteropexy, 85%; native tissue repair, 67%). From rest to strain, failures (vs successes) had greater inferior displacement of the vaginal apex (difference, -12 mm; 95% confidence interval, -19 to -6) and perineal body (difference, -7 mm; 95% confidence interval, -11 to -4) and elongation of the anterior vaginal wall (difference, 12 mm; 95% confidence interval, 8-16) and vaginal introitus (difference, 11 mm; 95% confidence interval, 7-15).ConclusionThe primary mechanism of prolapse recurrence following vaginal hysterectomy with uterosacral ligament suspension or VM hysteropexy was apical descent. In addition, greater inferior descent of the vaginal apex and perineal body, lengthening of the anterior vaginal wall, and increased size of the vaginal introitus with strain were associated with anatomic failure. Further studies are needed to provide additional insight into the mechanism by which these factors contribute to anatomic failure.

Published
2021

11. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial.

Author

Harvie, Heidi, Amundsen, Cindy, Neuwahl, Simon, Honeycutt, Amanda, Sung, Vivian, Rogers, Rebecca, Ellington, David, Ferrando, Cecile, Chermansky, Christopher, Mazloomdoost, Donna, Thomas, Sonia, and Lukacz, Emily

Subjects
botulinum toxins, cost-benefit analysis, transcutaneous electric nerve stimulation, type A, urge, urinary incontinence, Botulinum Toxins, Type A, Cost-Benefit Analysis, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Health Care Costs, Humans, Lumbosacral Plexus, Male, Middle Aged, Prospective Studies, Time Factors, Transcutaneous Electric Nerve Stimulation, Treatment Outcome, Urinary Incontinence, Urge, Urination
Abstract

PURPOSE: Sacral neuromodulation and intradetrusor onabotulinumtoxinA injection are therapies for refractory urgency urinary incontinence. Sacral neuromodulation involves surgical implantation of a device that can last 4 to 6 years while onabotulinumtoxinA therapy involves serial office injections. We assessed the cost-effectiveness of 2-stage implantation sacral neuromodulation vs 200 units onabotulinumtoxinA for the treatment of urgency urinary incontinence. MATERIALS AND METHODS: Prospective economic evaluation was performed concurrent with the ROSETTA (Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment) randomized trial of 386 women with 6 or more urgency urinary incontinence episodes on a 3-day diary. Analysis is from the health care system perspective with primary within-trial analysis for 2 years and secondary 5-year decision analysis. Costs are in 2018 U.S. dollars. Effectiveness was measured in quality adjusted life-years (QALYs) and reductions in urgency urinary incontinence episodes per day. We generated incremental cost-effectiveness ratios and cost-effectiveness acceptability curves. RESULTS: Two-year costs were higher for sacral neuromodulation than for onabotulinumtoxinA ($35,680 [95% CI 33,920-37,440] vs $7,460 [95% CI 5,780-9,150], p

Published
2020

12. Reply by Authors.

Author

Harvie, Heidi S, Amundsen, Cindy L, Neuwahl, Simon J, Honeycutt, Amanda A, Lukacz, Emily S, Sung, Vivian W, Rogers, Rebecca G, Ellington, David, Ferrando, Cecile A, Chermansky, Christopher J, Mazloomdoost, Donna, and Thomas, Sonia

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Urology & Nephrology, Clinical sciences
Published
2020

13. Cost-Effectiveness of Sacral Neuromodulation versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: Results of the ROSETTA Randomized Trial.

Author

Harvie, Heidi S, Amundsen, Cindy L, Neuwahl, Simon J, Honeycutt, Amanda A, Lukacz, Emily S, Sung, Vivian W, Rogers, Rebecca G, Ellington, David, Ferrando, Cecile A, Chermansky, Christopher J, Mazloomdoost, Donna, and Thomas, Sonia

Subjects
Lumbosacral Plexus, Humans, Treatment Outcome, Transcutaneous Electric Nerve Stimulation, Follow-Up Studies, Prospective Studies, Urination, Dose-Response Relationship, Drug, Time Factors, Middle Aged, Cost-Benefit Analysis, Health Care Costs, Female, Male, Urinary Incontinence, Urge, Botulinum Toxins, Type A, botulinum toxins, cost-benefit analysis, transcutaneous electric nerve stimulation, type A, urge, urinary incontinence, Dose-Response Relationship, Drug, Urinary Incontinence, Urge, Botulinum Toxins, Type A, Clinical Trials and Supportive Activities, Cost Effectiveness Research, Health Services, Comparative Effectiveness Research, Urologic Diseases, Clinical Research, Urology & Nephrology, Clinical Sciences
Abstract

PurposeSacral neuromodulation and intradetrusor onabotulinumtoxinA injection are therapies for refractory urgency urinary incontinence. Sacral neuromodulation involves surgical implantation of a device that can last 4 to 6 years while onabotulinumtoxinA therapy involves serial office injections. We assessed the cost-effectiveness of 2-stage implantation sacral neuromodulation vs 200 units onabotulinumtoxinA for the treatment of urgency urinary incontinence.Materials and methodsProspective economic evaluation was performed concurrent with the ROSETTA (Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment) randomized trial of 386 women with 6 or more urgency urinary incontinence episodes on a 3-day diary. Analysis is from the health care system perspective with primary within-trial analysis for 2 years and secondary 5-year decision analysis. Costs are in 2018 U.S. dollars. Effectiveness was measured in quality adjusted life-years (QALYs) and reductions in urgency urinary incontinence episodes per day. We generated incremental cost-effectiveness ratios and cost-effectiveness acceptability curves.ResultsTwo-year costs were higher for sacral neuromodulation than for onabotulinumtoxinA ($35,680 [95% CI 33,920-37,440] vs $7,460 [95% CI 5,780-9,150], p

Published
2020

25. Challenges and innovations in training gyn surgeons: Educators are responding to the problematic issues involving ObGyn resident surgical training with strategies that encompass tracking and simulation

Author

Baker, Mary V., Butler, Brandy M., Murarka, Shivani M., Ferrando, Cecile A., Miyazaki, Douglas W., and Zimmerman, Carl W.

Subjects
Surgeons -- Analysis -- Training, Obstetrics -- Analysis, Health
Abstract

Obstetrics and gynecology (ObGyn) is a surgical specialty, yet the training of ObGyn residents differs significantly from that of residents in other surgical specialties. In addition to attaining competency in [...]

Published
2022
Full Text
View/download PDF

29. Gender-Affirming Vaginoplasty: A Comparison of Algorithms, Surgical Techniques and Management Practices across 17 High-volume Centers in North America and Europe

Author

Coon, Devin, Morrison, Shane D., Morris, Martin P., Keller, Patrick, Bluebond-Langner, Rachel, Bowers, Marci, Brassard, Pierre, Buncamper, Marlon E., Dugi, Daniel, III, Ferrando, Cecile, Gast, Katherine M., McGinn, Christine, Meltzer, Toby, Monstrey, Stan, Özer, Müjde, Poh, Melissa, Satterwhite, Thomas, Ting, Jess, Zhao, Lee, Kuzon, William M., and Schechter, Loren

Published
2023
Full Text
View/download PDF

42. Innovative therapies in gynecology: The evidence and your practice: Nonsurgical, nonhormonal novel treatments appear promising for treating such disorders as GSM and SUI, but is the evidence of efficacy and safety sufficient to bear them out?

Author

Murphy, Miles, Ferrando, Cecile, Shobeiri, S. Abbas, and Pezzella, Andrea

Subjects
United States. Food and Drug Administration, Hydroxylapatite, Health insurance industry, Health
Abstract

As more and more gynecologic therapies move to the outpatient setting, keeping up on the latest data regarding emerging options can be challenging. Furthermore, it can be difficult to justify [...]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results